Management ChangeJul 16, 2026, 08:41 AM
Harmony Biosciences Q2 Revenue $261M; Reaffirms FY26 Guidance; CFO Departs
AI Summary
Harmony Biosciences announced preliminary record net product revenue of approximately $261 million for the second quarter of 2026, representing 30% year-over-year growth. The company also reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. Concurrently, Harmony Biosciences announced that its Chief Financial Officer, Glenn Reicin, has stepped down, and Stephen Mollichella, SVP and Controller, has been appointed as Interim Principal Financial Officer.
Key Highlights
- Glenn Reicin stepped down as Chief Financial Officer, effective July 16, 2026.
- Stephen Mollichella appointed Interim Principal Financial Officer, effective July 16, 2026.
- Preliminary Q2 2026 net product revenue for WAKIX was approximately $261 million.
- Q2 2026 net product revenue grew 30% year over year.
- Q2 2026 net product revenue grew 21% quarter over quarter.
- Reaffirmed full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
Price Impact
More from HRMY